Nkarta, Inc. (NKTX)
NASDAQ: NKTX · Real-Time Price · USD
1.120
-0.030 (-2.61%)
At close: Nov 19, 2026, 4:00 PM EST
1.130
+0.010 (0.89%)
After-hours: Nov 19, 2026, 7:30 PM EST
Nkarta Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
103
Market Cap
80.31M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Black Diamond Therapeutics | 70.00M |
| Cellectis | 32.10M |
| Seer, Inc. | 14.08M |
| Rani Therapeutics Holdings | 6.58M |
| Kazia Therapeutics | 1.32M |
| Rallybio | 434.00K |
NKTX News
- 8 days ago - Nkarta announces integrated safety results from 40 patients treated with NKX019 - TheFly
- 8 days ago - Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026 - GlobeNewsWire
- 10 days ago - Nkarta Transcript: Study update - Transcripts
- 10 days ago - Nkarta Press release: Study update - Filings
- 10 days ago - Nkarta Slides: Study update - Filings
- 10 days ago - Nkarta announces initial clinical data from Ntrust clinical trial program - TheFly
- 10 days ago - Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence - GlobeNewsWire
- 13 days ago - Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 - GlobeNewsWire